Acacia Pharma gets USFDA nod of BARHEMSYS® (amisulpride) for Treatment, Prevention of PONV Medical Dialogues Bureau8 March 2020 4:30 AM GMTThe approval for BARHEMSYS covers the treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or who...